VIRUSSOUL Updated   
Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600

Lupin gets USFDA nod to market pain relief, colonoscopy drugs and also gets FDA approval for generic Percocet tablets .
Lupin recently received FDA approval for generic Suprep Bowel Prep Kit and Suprep kit approval It may add 5% to Lupin’s EPS for FY18 earnings .
In addition the pharma major’s Goa facility has been cleared by the US FDA.

Lupin Result: Revenue grew 26% YoY to INR 44.8b Gross margin was stable QoQ at 71.0%. EBITDA rose 27% YoY to INR 12.2b with margin of 27% . EBITDA margin improvement was primarily driven by strong growth in US sales (+53% YoY, +8% QoQ; despite R&D as % of sales at 12.9%) and forex gain of INR 270m. PAT of INR 6.3b was impacted by 1% due to a high tax rate of 39%.

Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
Trade active:
Trade Activated @1473.00 for a Target of 1600 with SL 1420.
Trade closed: target reached:
The Pharma sector seems to be weak and recently Divis had problems on USFDA Approvals , So use this rally to exit in LUPIN as we can enter later at a lower price. Buy initiated @1470 Lupin closed @ 1490 for a profit of 20. #SB7

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.